Research in Experimental Medicine

, Volume 193, Issue 1, pp 97–103 | Cite as

Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7–36) amide on the rat pancreas

  • Rüdiger Göke
  • Birte Wagner
  • Hans-Christoph Fehmann
  • Burkhard Göke
Original Papers

Abstract

The glucose-dependent action of GLP-1 (7–36) amide (GLP-1) on insulin secretion was studied in isolated islets and in the perfused rat pancreas. In islet experiments in the presence of non-stimulatory glucose levels (<3 mmol/1) a GLP-1 concentration of 10 nmol/1 increased insulin secretion by 83%. However, higher GLP-1 concentrations (25 and 100 nmol/l) could not further enhance this effect (85 and 83%, respectively). The onset of the stimulatory action of a supramaximal GLP-1-load (25 nmol/l) was at a glucose level of 3 mmol/l. In the perfused pancreas, 25 nmol/l GLP-1 induced a strong insulin release at 5 mmol/l glucose, but under basal glucose (2.8 mmol/l) only a slight enhancement of insulin secretion occurred during the late phase (30 to 54 min) of perfusion (P<0.05). In conclusion, a slight but not dose-dependent stimulation of insulin secretion by supramaximal GLP-1 loads under basal glucose levels was found. The necessary GLP-1 concentrations to achieve this in vitro effect are beyond physiological or postprandial levels.

Key words

Glucagon-like peptide-1 Islets Perfused pancreas Insulin secretion Glucose dependency 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bailey, CJ, Flatt PR (1987) Glucagon-like peptide 1 and the entero-insulinar axis in obese hyperglycemic mice. Life Sci 40:521–525PubMedCrossRefGoogle Scholar
  2. 2.
    Creutzfeldt W (1980) Insulinotropic factors of the gut—the broadening incretin concept. Gastroenterology 78:1631–1632.PubMedGoogle Scholar
  3. 3.
    Creutzfeldt W, Ebert R (1985) New developments in the incretin concept. Diabetologia 28:565–573PubMedCrossRefGoogle Scholar
  4. 4.
    Ebert R (1990) Gut signals for islet hormone release. Eur J Clin Invest 20 (S1): 20–26Google Scholar
  5. 5.
    Elliott R, Morgan L, Tredger, J, Charles S, Wright J, Marks V (1991) The effects of carbohydrate, fat and protein on glucagon-like peptide-1 secretion in man (abstract). J Endocrinol 131 [Suppl] 62Google Scholar
  6. 6.
    Fehmann HC, Göke R, Göke B (1992) Glucagon-like peptide 1 (7–37)/(7–36) amide is a new incretin hormone. Mol Cell Endocrinol 85: C39-C44PubMedCrossRefGoogle Scholar
  7. 7.
    Fridolf T, Böttcher G, Sundler F, Ahren B (1991) GLP-1 and GLP-1 (7–36) amide: Influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 6: 208–215PubMedCrossRefGoogle Scholar
  8. 8.
    Göke, B, Elsebach K, Hausmann W, Schaar M, Arnold R, Adler G (1987) Endocrine pancreatic morphology and function in exocrine insufficiency in rats. Am J Physiol 253:G139–145PubMedGoogle Scholar
  9. 9.
    Göke, R, Fehmann HC, Göke B (1991) Glucagon-like peptide 1 (7–36) amide is a new incretin enterogastrone candidate. Eur J Clin Invest 21: 135–144PubMedCrossRefGoogle Scholar
  10. 10.
    Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y, Yamashita K (1989) Comparison of the effects of glucagon-like peptide 1 (1–37) and −(7–37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 124: 1768–1773PubMedCrossRefGoogle Scholar
  11. 11.
    Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S (1989) Glucagonostatic and insulinotropic actin of glucagonlike peptide 1(7–36) amide. Diabetes 38:902–905PubMedCrossRefGoogle Scholar
  12. 12.
    Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide 1(7–36): a physiological incretin in man. Lancet II:1300–1304CrossRefGoogle Scholar
  13. 13.
    Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39PubMedGoogle Scholar
  14. 14.
    McIntyre N, Holdsworth CD, Turner DS (1964) New interpretation of oral glucose tolerance. Lancet II: 20–21CrossRefGoogle Scholar
  15. 15.
    Miholic J, Orskov C, Holst JJ, Kotzerke J, Meyer HJ (1991) Emptying of the the gastric substitute, glucagon-like peptide 1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36: 1361–1370PubMedCrossRefGoogle Scholar
  16. 16.
    Orskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of non-insulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415–423PubMedGoogle Scholar
  17. 17.
    Shima K, Hirota M, Ohboshi C (1988) Effect of glucagon-like peptide-1 on insulin secretion. Regul Peptides 22: 245–252CrossRefGoogle Scholar
  18. 18.
    Siegel EG, Creutzfeldt W (1988) Hormone responsiveness of collagenase-isolated rat islets is markedly increased by short-term maintenance in tissue culture. Horm Metab Res 20: 184–185PubMedCrossRefGoogle Scholar
  19. 19.
    Weir GC, Mojsov S, Hendrick GK, Habener JF (1989) Glucagonlike peptide 1 (7–37) actions on endocrine pancreas. Diabetes 38: 338–342PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Rüdiger Göke
    • 1
  • Birte Wagner
    • 1
  • Hans-Christoph Fehmann
    • 1
  • Burkhard Göke
    • 1
  1. 1.Laboratory of Molecular Endocrinology, Division of Gastroenterology, Department of Internal MedicinePhilipps University of MarburgMarburgGermany

Personalised recommendations